Neurology

Symptoms and Biology: Differentiating from Muscular Dystrophy

At a Glance

Congenital myopathy is a structural muscle defect present from birth, unlike muscular dystrophy, which causes progressive muscle breakdown. Because the muscle isn't actively dying, children with congenital myopathy typically have normal CK blood test levels and do not experience progressive muscle loss.

When a child is diagnosed with a muscle condition, many parents immediately encounter information about Muscular Dystrophy (MD). It is critical to understand that Congenital Myopathy (CM) is a fundamentally different condition. While both cause muscle weakness, the “why” and “how” are different at a biological level.

The Biological Mechanism: Structure vs. Breakdown

To understand the difference, imagine a car.

Muscular Dystrophy is like a car with a leaking fuel tank or a body that is rusting away. The muscle cells are missing a “protective glue” (like the protein dystrophin). Without this glue, the muscle cells break down (necrosis) every time they are used and are eventually replaced by fat or scar tissue ^[1]^[2].
Congenital Myopathy is like a car that was built with an engine part slightly out of alignment. The muscle cells aren’t dying or “rusting.” Instead, the internal machinery—the sarcomere (the parts that pull the muscle tight) or the T-tubules (the “electrical wiring” that tells the muscle to move)—has a structural defect from birth ^[3]^[4]^[5].

Because the cells aren’t actively dying, the condition is usually non-dystrophic, meaning it does not typically result in the progressive muscle loss seen in muscular dystrophies ^[6].

The CK Blood Test: A Key Clue

Doctors often use a blood test called Creatine Kinase (CK) to help tell these two apart. CK is an enzyme that lives inside healthy muscle cells. When a muscle cell breaks down or dies, it “leaks” CK into the bloodstream.

In Muscular Dystrophy: Because muscle cells are constantly breaking down, CK levels in the blood are often massively elevated (sometimes 10 to 50 times the normal limit) ^[1]^[7].
In Congenital Myopathy: Because the muscle cells are structurally different but generally stable, the CK level is usually normal or only slightly elevated ^[8]^[9].

Classic Early Symptoms in Infants

Congenital myopathies typically show up early, often in the first days or weeks of life. These symptoms are related to the “floppy” nature of the muscles (hypotonia).

Respiratory Weakness: This is often the most critical symptom. Infants may have shallow breathing or a weak cry, and some may need a machine to help them breathe (mechanical ventilation) right at birth ^[10]^[11].
Bulbar Dysfunction (Feeding and Swallowing): The muscles used for sucking and swallowing may be weak. This can make feeding very slow or cause “aspiration,” where milk accidentally enters the lungs instead of the stomach ^[10]^[12].
Delayed Motor Milestones: Because of the underlying weakness, babies may take longer to hold up their heads, roll over, or sit up. However, many children continue to make slow, steady progress in these areas over time ^[6]^[13].

Understanding that your child’s condition is about how the muscle is built rather than how it is breaking down can help shift the focus toward the specialized physical therapies and respiratory supports that help children with congenital myopathy thrive ^[14]^[15].

Common questions in this guide

What is the difference between congenital myopathy and muscular dystrophy?

Muscular dystrophy causes progressive muscle breakdown due to missing protective proteins. Congenital myopathy involves a structural defect in the muscle machinery from birth, meaning the muscles are weak but do not actively break down or die.

Why is the CK blood test used to diagnose muscle conditions?

Creatine Kinase (CK) is an enzyme that leaks into the blood when muscle cells break down. In muscular dystrophy, CK levels are massively elevated, whereas in congenital myopathy, they are usually normal or only slightly elevated.

What are the classic early symptoms of congenital myopathy in infants?

Early signs often include severe muscle floppiness (hypotonia), respiratory weakness, and feeding difficulties. Babies may have a weak cry, struggle to swallow safely, and experience delays in reaching motor milestones.

Will my child with congenital myopathy lose muscle function over time?

Because congenital myopathy is typically non-dystrophic, it does not usually cause the progressive muscle loss seen in muscular dystrophies. Many children actually make slow, steady progress in their motor skills over time with physical therapy.

What does it mean that my child has a structural defect in their muscles?

A structural defect means the internal machinery of the muscle cell, such as the sarcomere or T-tubules, is built incorrectly due to a genetic mutation. This affects how the muscle contracts and functions, but it does not cause the cell to break down.

Curated prompts to bring to your next appointment.

1.What was my child’s specific CK level, and how does it compare to the 'normal' range for an infant?
2.Can you explain the specific genetic mutation found and how it affects the 'contractile machinery' of the muscle?
3.Is my child's current level of respiratory strength expected for this diagnosis, or should we be using extra support (like BiPAP) during sleep?
4.How frequently should we monitor my child's swallowing safety, and are there specific textures of food we should avoid?
5.Does this diagnosis change the way we should treat my child if they get a common respiratory virus like a cold or the flu?

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References (15)

1
Diagnostic Accuracy of Creatine Kinase Isoenzyme-MM Test in Newborn Screening for Duchenne Muscular Dystrophy: A Systematic Review and Meta-Analysis.
Tang L, Pan M, Wu F
Pediatric neurology 2024; (153()):84-91 doi:10.1016/j.pediatrneurol.2024.01.010.
PMID: 38350306
2
Creatine kinase test diagnostic accuracy in neonatal screening for Duchenne Muscular Dystrophy: A systematic review.
de Freitas Nakata KC, da Silva Pereira PP, Salgado Riveros B
Clinical biochemistry 2021; (98()):1-9 doi:10.1016/j.clinbiochem.2021.09.010.
PMID: 34626608
3
Duplex signaling by CaM and Stac3 enhances CaV1.1 function and provides insights into congenital myopathy.
Niu J, Yang W, Yue DT, et al.
The Journal of general physiology 2018; (150(8)):1145-1161 doi:10.1085/jgp.201812005.
PMID: 29950399
4
Structure and function of STAC proteins: Calcium channel modulators and critical components of muscle excitation-contraction coupling.
Rufenach B, Van Petegem F
The Journal of biological chemistry 2021; (297(1)):100874 doi:10.1016/j.jbc.2021.100874.
PMID: 34129875
5
Tirasemtiv enhances submaximal muscle tension in an Acta1:p.Asp286Gly mouse model of nemaline myopathy.
Galli RA, Borsboom TC, Gineste C, et al.
The Journal of general physiology 2024; (156(4)) doi:10.1085/jgp.202313471.
PMID: 38376469
6
Therapeutic Aspects in Congenital Myopathies.
Jungbluth H, Muntoni F
Seminars in pediatric neurology 2019; (29()):71-82 doi:10.1016/j.spen.2019.01.004.
PMID: 31060727
7
Duchenne Muscular Dystrophy Newborn Screening: Evaluation of a New GSP® Neonatal Creatine Kinase-MM Kit in a US and Danish Population.
Timonen A, Lloyd-Puryear M, Hougaard DM, et al.
International journal of neonatal screening 2019; (5(3)):27 doi:10.3390/ijns5030027.
PMID: 33072986
8
Identifying Non-Duchenne Muscular Dystrophy-Positive and False Negative Results in Prior Duchenne Muscular Dystrophy Newborn Screening Programs: A Review.
Gatheridge MA, Kwon JM, Mendell JM, et al.
JAMA neurology 2016; (73(1)):111-6 doi:10.1001/jamaneurol.2015.3537.
PMID: 26594870
9
Genetic and Early Clinical Manifestations of Females Heterozygous for Duchenne/Becker Muscular Dystrophy.
Papa R, Madia F, Bartolomeo D, et al.
Pediatric neurology 2016; (55()):58-63.
PMID: 26718981
10
Profound Hypotonia and Respiratory Failure due to Suspected Nemaline Myopathy in a Preterm Infant.
Akuamoah-Boateng G, Stetson RC, Kaemingk BD, et al.
AJP reports 2021; (11(2)):e91-e94 doi:10.1055/s-0041-1728782.
PMID: 34178423
11
Expanding the spectrum of congenital myopathy linked to recessive mutations in SCN4A.
Mercier S, Lornage X, Malfatti E, et al.
Neurology 2017; (88(4)):414-416 doi:10.1212/WNL.0000000000003535.
PMID: 28003497
12
Expanding the Spectrum of Congenital Myopathy Linked to Variants in the MYBPC1 Gene: A Clinical Report.
Lanvin PL, Li D, Conrad S, et al.
Neurology. Clinical practice 2024; (14(3)):e200228 doi:10.1212/CPJ.0000000000200228.
PMID: 38690148
13
Phenotypic Spectrum of DNM2-Related Centronuclear Myopathy.
Hayes LH, Perdomini M, Aykanat A, et al.
Neurology. Genetics 2022; (8(6)):e200027 doi:10.1212/NXG.0000000000200027.
PMID: 36324371
14
Exercise Training as Part of Musculoskeletal Management for Congenital Myopathy: Where Are We Now?
Adaikina A, Hofman PL, O'Grady GL, Gusso S
Pediatric neurology 2020; (104()):13-18 doi:10.1016/j.pediatrneurol.2019.10.008.
PMID: 31926608
15
[The influence of hydrokinesitherapy on motor and cardiorespiratory functions in hereditary myopathy of childhood].
Suslov VM, Lieberman LN, Ponomarenko GN, et al.
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova 2024; (124(11. Vyp. 2)):88-95 doi:10.17116/jnevro202412411288.
PMID: 39576166

This page explains the biological differences between congenital myopathy and muscular dystrophy for educational purposes. Always consult your pediatric neurologist regarding your child's specific diagnosis, lab results, and care plan.

Get notified when new evidence is published on Congenital myopathy.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Guide Contents